A study to find out how safe is it to give people a new medicine for asthma (GDC-4379), and to see how this medicine is processed in the body
Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of inhaled GDC-4379 conducted in three parts: A single-ascending dose study in healthy volunteers, a multiple-ascending dose study in healthy volunteers, and a proof-of-activity study in patients with mild asthma
Healthy Volunteers
Basic Details
This clinical trial was done to study a new medicine called, “GDC-4379”, for the treatment of asthma. This study investigated whether it was safe to give people single and multiple doses of GDC-4379. Researchers also wanted to find out what happened to GDC-4379 in the body, and if there was any indication that GDC-4379 may be useful in patients with asthma. One hundred and twenty-eight healthy people and patients with asthma took part in this study at two study centers in one country.
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
For the latest version of this information please go to www.forpatients.roche.com